Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 35.85B +27.0% |
| Revenue (ttm) | 3.10B +31.7% |
| Net Income | -751.18M |
| EPS | -0.74 |
| Shares Out | 1.03B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 809,800 |
| Open | 21.02 |
| Previous Close | 21.00 |
| Day's Range | 20.24 - 21.26 |
| 52-Week Range | 15.66 - 38.64 |
| Beta | 0.61 |
| Analysts | Strong Buy |
| Price Target | 29.93 (+47.73%) |
| Earnings Date | Aug 26, 2026 |
About HKG:1877
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company’s product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in phase III clinical trial to treat psoriatic and spondylitis; JS001sc, a subcutaneous injection which is in phase III clinical trial for the treatment of t... [Read more]
Financial Performance
In 2025, HKG:1877's revenue was 2.50 billion, an increase of 28.23% compared to the previous year's 1.95 billion. Losses were -875.17 million, -31.68% less than in 2024.
Financial numbers in CNY Financial StatementsNews
Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC
SHANGHAI, May 26, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the di...
Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026
Results from early clinical studies across Junshi Biosciences' innovative pipeline were presented at the 2026 AACR, featuring: JS212 (EGFR/HER3 ADC), the J
Junshi Biosciences Announces 2025 Full Year Financial Results and Provides Corporate Updates
SHANGHAI, March 13, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to th...
Shanghai Junshi announces NMPA acceptance of NDAs for toripalimab injection
Shanghai Junshi (SHJBF) Biosciences announced that the new drug applications for the company’s product, toripalimab injection, for 12 indications in the treatment of tumors has been accepted by the Na...
Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications
SHANGHAI, March 09, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ...
Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)
SHANGHAI and HONG KONG, Feb. 24, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discoveri...
Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)
SHANGHAI, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the d...
Shanghai Junshi announces results from JUPITER-02, JUPITER-06 at ESMO
Shanghai Junshi (SHJBF) Biosciences announced new and promising long-term survival results from JUPITER-02 and JUPITER-06 at the European Society for Medical Oncology, ESMO, ASIA Congress 2025. JUPITE...
Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis
SHANGHAI, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the d...
Junshi Biosciences Announces Primary Endpoints Met in JS001sc's Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC
SHANGHAI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the d...
Junshi Biosciences Announces FDA's Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients
SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the d...
Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
JS005 has achieved positive results in a multi-center, randomized, double-blind, parallel, placebo-controlled pivotal registrational Phase 3 clinical study
TREOS Bio Partners with Charité Berlin and Junshi Biosciences to Launch Pivotal Phase II Clinical Trial in Refractory MSS Colorectal Cancer
Bridge financing of $2.1 million supports initiation of pivotal Phase II study in 140 patients with microsatellite stable metastatic colorectal cancer, addressing 85% of CRC cases with limited treatme...
Junshi Biosciences Announces 2025 Interim Financial Results and Provides Corporate Updates
SHANGHAI, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the...